Clinical Trial Update: Phase I Clinical Study of MBS301 in Treatment of HER2 Positive Recurrent or Metastatic Malignant Solid Tumor [Phase 1]

View source ↗

Summary

Phase I clinical trial update for MBS301 in HER2-positive recurrent or metastatic malignant solid tumors; study is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• MBS301

Snippet

Sponsor: Beijing Mabworks Biotech Co., Ltd. | Conditions: HER2-positive Recurrent or Metastatic Malignant Solid Tumor | Phase 1 | Status: RECRUITING